Berobenatide (PF-3944) 10 Phase 3 obesity studies to start in 2026
Berobenatide (PF-3944) 10 Phase 3 obesity studies to start in 2026, expected during 2026 (no exact date yet). A company milestone for Pfizer (berobenatide (PF'3944) for Chronic weight management and obesity comorbidities (knee OA, OSA)): a step in the program rather than a decision or a data readout.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary
- Company
- Pfizer Inc. PFE
- Drug
- berobenatide (PF'3944)
- For
- Chronic weight management and obesity comorbidities (knee OA, OSA)
- Stage
- Phase 3 · the last stage before a drug can be approved
- When
- 2026 · the company gave a window, not a day; the calendar never invents one
- Source note
- Pfizer Q2 2026 earnings release (Aug 4, 2026), following June 2026 VESPER-1/2/3 Phase 2b data for the monthly GLP-1 RA peptide; part of a 20+ trial obesity program.
- Checked
- Checked by a person when it was added
- Source: s206.q4cdn.com ↗ — where this entry was taken from
- SEC filings (8-K) ↗ — press releases are attached to 8-K filings
- ClinicalTrials.gov ↗ — trials of this drug
- PFE headlines on this site
Pfizer expects to report results from its Phase 3 study of mevrometostat (PF-06821497) for 1-2L metastatic castration-resistant prostate cancer post-abiraterone (MEVPRO-1) during 2026 (no exact date yet). Phase 3 is the last stage before a drug can be approved, so this result usually decides the program’s future.
More details
- Entry
- Mevrometostat MEVPRO-1 Ph3 mCRPC readout · Clinical trial results (readout / topline data)
- Drug
- mevrometostat (PF-06821497)
- For
- 1-2L metastatic castration-resistant prostate cancer post-abiraterone (MEVPRO-1)
- Stage
- Phase 3 · the last stage before a drug can be approved
- When
- 2026 · the company gave a window, not a day
- Source note
- Listed on Pfizer's 'Key Anticipated 2026 Catalysts' page under anticipated data readouts (year-level timing).
- Checked
- Checked by a person when it was added
- Verify it
- Source: pfizer.com ↗ — where this entry was taken from
- SEC filings (8-K) ↗ — press releases are attached to 8-K filings
- ClinicalTrials.gov ↗ — trials of this drug
- PFE headlines on this site
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
PD-1xVEGF (PF'4404) pivotal study starts incl. 1L NSCLC, expected during 2026 (no exact date yet). A company milestone for Pfizer (PF-08634404 (PD-1xVEGF bispecific) for 1L squamous/non-squamous NSCLC and other tumors): a step in the program rather than a decision or a data readout.
More details
- Entry
- PD-1xVEGF (PF'4404) pivotal study starts incl. 1L NSCLC · Company milestone
- Drug
- PF-08634404 (PD-1xVEGF bispecific)
- For
- 1L squamous/non-squamous NSCLC and other tumors
- Stage
- Phase 3 · the last stage before a drug can be approved
- When
- 2026 · the company gave a window, not a day
- Source note
- Pfizer's 'Key Anticipated 2026 Catalysts' page lists pivotal study starts for the PD-1xVEGF bispectific in 2026 (also PD-1xVEGF + PADCEV in 1L mUC); year-level timing only.
- Checked
- Checked by a person when it was added
- Verify it
- Source: pfizer.com ↗ — where this entry was taken from
- SEC filings (8-K) ↗ — press releases are attached to 8-K filings
- ClinicalTrials.gov ↗ — trials of this drug
- PFE headlines on this site
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
The FDA is expected to decide in Q4 2026 (Oct–Dec) (no exact date yet) whether to approve Pfizer’s TALZENNA (talazoparib) + XTANDI (enzalutamide) for HRR gene-altered metastatic castration-sensitive prostate cancer. Approval clears it for sale in the US; a rejection usually arrives as a letter listing what has to be fixed first.
More details
- Entry
- PDUFA for TALZENNA + XTANDI in HRR-mutated mCSPC · FDA decision due (PDUFA date)
- Drug
- TALZENNA (talazoparib) + XTANDI (enzalutamide)
- For
- HRR gene-altered metastatic castration-sensitive prostate cancer
- Stage
- sNDA under Priority Review
- When
- Q4 2026 · the company gave a window, not a day
- Source note
- FDA granted Priority Review to the sNDA based on Phase 3 TALAPRO-3 (52% reduction in risk of radiographic progression or death). Pfizer's release states a PDUFA action date in the last quarter of 2026; no exact day disclosed.
- Checked
- Checked by a person when it was added
- Verify it
- Source: pfizer.com ↗ — where this entry was taken from
- SEC filings (8-K) ↗ — press releases are attached to 8-K filings
- ClinicalTrials.gov ↗ — trials of this drug
- Drugs@FDA ↗ — search the drug name for approval letters
- PFE headlines on this site
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
The FDA is expected to decide in Q4 2026 (Oct–Dec) (no exact date yet) whether to approve Pfizer’s TUKYSA (tucatinib) + trastuzumab + pertuzumab for HER2-positive metastatic breast cancer. Approval clears it for sale in the US; a rejection usually arrives as a letter listing what has to be fixed first.
More details
- Entry
- Estimated PDUFA for TUKYSA combination in HER2+ metastatic breast cancer · FDA decision due (PDUFA date)
- Drug
- TUKYSA (tucatinib) + trastuzumab + pertuzumab
- For
- HER2-positive metastatic breast cancer
- Stage
- Supplemental application
- When
- Q4 2026 · the company gave a window, not a day
- Source note
- Catalyst tracker pdufa.bio lists a Q4 2026 (estimated) FDA action date for the TUKYSA combination in HER2+ MBC. No Pfizer press release stating the date was located, so treated as an estimate.
- Checked
- Checked by a person when it was added
- Verify it
- Source: pdufa.bio ↗ — where this entry was taken from
- SEC filings (8-K) ↗ — press releases are attached to 8-K filings
- ClinicalTrials.gov ↗ — trials of this drug
- Drugs@FDA ↗ — search the drug name for approval letters
- PFE headlines on this site
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
35-valent pneumococcal vaccine adult candidate to enter clinic by end of 2026, expected in Q4 2026 (Oct–Dec) (no exact date yet). A company milestone for Pfizer (PCV35 (fifth-generation pneumococcal conjugate vaccine) for Pneumococcal disease, adults): a step in the program rather than a decision or a data readout.
More details
- Entry
- 35-valent pneumococcal vaccine adult candidate to enter clinic by end of 2026 · Company milestone
- Drug
- PCV35 (fifth-generation pneumococcal conjugate vaccine)
- For
- Pneumococcal disease, adults
- Stage
- Phase 1 · an early safety study in a small group of people
- When
- Q4 2026 · the company gave a window, not a day
- Source note
- Pfizer Q2 2026 earnings release (Aug 4, 2026); PCV25 (PF-07872412) pediatric pivotal Phase 3 already began in May 2026. 'By end of 2026' mapped to Q4 2026.
- Checked
- Checked by a person when it was added
- Verify it
- Source: s206.q4cdn.com ↗ — where this entry was taken from
- SEC filings (8-K) ↗ — press releases are attached to 8-K filings
- ClinicalTrials.gov ↗ — trials of this drug
- PFE headlines on this site
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page